Tissue Microarray Market Report 2025

The tissue microarray market size has grown strongly in recent years. It will grow from $12.05 billion in 2024 to $13.23 billion in 2025 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to rise of precision medicine, drug discovery and development, efficient analysis, rising prevalence of chronic diseases, biobanking initiatives.

The tissue microarray market size is expected to see rapid growth in the next few years. It will grow to $20.95 billion in 2029 at a compound annual growth rate (CAGR) of 12.2%. The growth in the forecast period can be attributed to emergence of digital pathology, expanded applications, growing biopharmaceutical industry, regulatory support and standards, ai and machine learning integration. Major trends in the forecast period include advancements in imaging technologies, development of 3d tissue microarrays, high-content screening, standardization initiatives, and single-cell analysis integration.

The increasing incidence of cancer is expected to drive the growth of the tissue microarray market in the future. Cancer encompasses a range of diseases that can arise in any organ or tissue when abnormal cells multiply uncontrollably, breach their normal boundaries, and potentially spread to other organs or invade nearby tissues. Tissue microarrays are utilized in oncology to analyze the expression of cancer-related biomarkers in different tumor samples. For example, in June 2022, data published by Macmillan Cancer Support, a UK-based cancer charity, indicated that the number of individuals living with cancer reached 3 million in 2022, with projections suggesting it will rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Therefore, the increasing number of cancer cases is driving the growth of the tissue microarray market.

The growth of the tissue microarray market is further fueled by the rising demand for personalized medicine. Personalized medicine tailors medical treatment to individual characteristics for more effective healthcare. Tissue microarrays are instrumental in analyzing multiple tissue samples concurrently, facilitating rapid assessment of biomarkers. In 2022, the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs), with approximately 34% classified as personalized medicines. This emphasizes the integral role of tissue microarrays in advancing personalized medicine.

A notable trend in the tissue microarray market is the emergence of strategic partnerships. Major companies in the market are forming alliances to develop innovative tissue microarray technologies. For instance, The Cureline Group partnered with Cellecta Inc. to launch Tissue 2 Target Services, combining their competencies in molecular analysis and biospecimen management. Another collaboration involves Ultivue Inc. and ngTMA, aiming to advance multiplexed immunofluorescence assays and apply new tissue microarray technologies for spatial analysis in scientific research.

Companies in the tissue microarray market are focusing on advanced solutions, such as microarray platforms, to enhance precision and efficiency in high-throughput tissue analysis. MARGenomics launched the Applied Biosystems GeneChip 3000 Dx v2, an advanced microarray platform, the first in Europe and the United States to receive regulatory approval for diagnostic purposes. This platform, funded by the Carlos III Health Institute and the European Union's NextGenerationEU initiative, offers diverse functionalities for genomic and expression microarrays.

In November 2022, The Cureline Group, a US-based company specializing in preclinical and clinical research services, announced a partnership with Cellecta Inc. to launch Tissue 2 Target, which aims to enhance preclinical and translational research workflows. This collaboration will create a comprehensive resource for researchers focused on gene target and biomarker discovery, streamlining the molecular characterization of high-quality human biospecimens. By leveraging The Cureline Group’s expertise in biospecimen management alongside Cellecta’s functional genomics techniques, the partnership seeks to facilitate evidence-based decision-making, ultimately improving the outcomes of translational and preclinical programs. Cellecta, Inc., also based in the US, specializes in functional genomics and offers innovative tools for RNA interference and CRISPR-based research.

Major companies operating in the tissue microarray market include Roche Group, Merck & Co. Inc., Thermo Fisher Scientific Inc., Becton, Dickinson Biosciences, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen NV, PerkinElmer Inc., Bio-Techne Corporation, Tristar Group, Evotec SE, Precision For Medicine Inc., Molecular Devices LLC, BioIVT LLC, BioChain Institute Inc., Creative Bioarray Co, 3DHISTECH Ltd., Novus Biologicals LLC, PREMIER Biosoft International Inc., iSpecimen Inc., OriGene Technologies Inc., Bio SB Inc., ProteoGenex Inc., Z Biotech LLC.

North America was the largest region in the tissue microarray market in 2024. Asia-Pacific is expected to be the fastest-growing region in the tissue microarray market report during the forecast period. The regions covered in the tissue microarray market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tissue microarray market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A tissue microarray is a high-throughput technology that enables comprehensive analysis of antigen expression across numerous tissues and cells in a single experiment, typically using paraffin blocks or formalin. It allows for the simultaneous assessment of protein expression in multiple tissue samples.

The primary types of tissue microarrays include immunohistochemistry, fluorescent in situ hybridization, frozen tissue array, and other variants. Immunohistochemistry (IHC) is a technique used to diagnose certain types of cancer, such as mesothelioma, by employing a visual marker to locate antigens in biopsy tissue. Various technologies such as DNA microarrays, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, western blotting, and others are utilized for applications in oncology, gene expression profiling, single nucleotide polymorphism (SNP) detection, double-stranded B-DNA microarrays, comparative genomic hybridization, sequencing bioinformatics, and more. These technologies find applications across different end-users, including pharmaceutical and biotechnological companies, research organizations, and hospitals.

The tissue microarray research report is one of a series of new reports that provides tissue microarray market statistics, including the tissue microarray industry's global market size, regional shares, competitors with tissue microarray market share, detailed tissue microarray market segments, market trends and opportunities, and any further data you may need to thrive in the tissue microarray industry. This tissue microarray market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tissue microarray market consists of sales of molds, needles, and tissue punches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.